Avastin for Prostate Cancer – Looks Like It Isn’t Going To Happen
Roche Pharmaceuticals has reported that their clinical trial of Avastin in men with advanced prostate cancer did not improve their overall life expectancy. […]
The FDA Has Approved TRELSTAR(R) 22.5 mg, The First 6-Month GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
Watson Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Trelstar – 22.5 mg (triptorelin pamoate for injectable suspension) at a dosage which will be required only to be administered twice a year. […]
On The Horizon – Cabazitaxel Extends Life After Chemotherapy Failure
The drug is called Cabazitaxel, (it will be named Jevtana) and is made by the French company Sanofi-Aventis SA. Cabazitaxel is a chemical cousin of Taxotere (the current standard of care) and it is designed to evade the mechanism that cancer cells use to resist Taxotere, so we can assume that initially it would be [...]
No Additional Hearing at the FDA for Provenge
According to a Reuters report, a spokeswomen from the FDA said yesterday that, “There is not going to be an additional advisory committee meeting” about the current application for the approval of Provenge. The FDA has the right to convene another meeting to discuss the results of the IMPACT trial, but it now looks as [...]
Docetaxel-Based Chemotherapy with Zoledronic Acid and Prednisone in Hormone Refractory Prostate Cancer: Factors Predicting Response and Survival
We know that docetaxel chemotherapy (chemo) extends life, but which men might hope to experience an increase in survival? The Department of Urology, All India Institute of Medical Sciences, New Delhi, India performed a small study designed to evaluate the efficacy of docetaxel/prednisone and zoledronic acid in the treatment of men with hormone refractory prostate [...]